Shares of Kenvue rebound today after Trump admin ties use of acetaminophen to autism

Industry Impact & Regulatory Response - The Trump administration advised pregnant women against taking acetaminophen (Tylenol) due to potential links to autism, triggering concerns and potential market reactions [1][2] - FDA is initiating a label update for Tylenol and similar products to reflect potential risks of neurological conditions like autism when taken during pregnancy [2] - The FDA's letter to doctors was more cautious, noting that while studies suggest an association between acetaminophen and autism, a causal relationship hasn't been established [3] - Global regulators like the WHO find no new evidence suggesting Tylenol poses a risk during pregnancy, contrasting with the US stance [8] - Medical communities such as the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine are not changing their views on Tylenol use during pregnancy [8][9] Company & Market Reaction - Ken View (likely referring to a company marketing acetaminophen products) is rebounding despite the announcement, suggesting investor resilience [1][11][14] - Ken View has been proactively pushing back against the alleged link between Tylenol and autism, asserting that no scientific evidence supports it [7] - GSK's old drug, Wooin, previously discontinued, may see its generic versions benefit from an updated label indicating potential use for autism symptoms [4] - GSK clarifies it has no plans to bring Wooin back to market, despite label updates potentially benefiting generic versions [4] Autism Treatment & Research - FDA is moving to approve an old GSK drug to treat autism symptoms, though studies are small and benefits may not be widespread [3][5] - The approved drug, currently used for cancer treatment toxicity, has shown promise in helping non-verbal autism patients, but further research is needed [5][6]